Back to results

CompletedPhase 3

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

NCT00099619

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Westmead, New South Wales, Australia

+25 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2004-09
Enrollment: 138 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (26)

Research SiteWestmead, New South Wales, Australia
Research SiteDaw Park, South Australia, Australia
Research SiteFullarton, South Australia, Australia
Research SiteBox Hill, Victoria, Australia
Research SiteEast Ringwood, Victoria, Australia
Research SiteAthens, Greece
Research SitePiraeus, Greece
Research SiteThessaloniki, Greece
Research SiteBudapest, Hungary
Research SiteGyula, Hungary
Research SitePécs, Hungary
Research SiteVeszprém, Hungary
Research SiteZalaegerszeg, Hungary
Research SiteBari, Italy
Research SiteBergamo, Italy
Research SiteCatania, Italy
Research SiteMilan, Italy
Research SitePerugia, Italy
Research SiteRome, Italy
Research SiteGuadalajara, Jalisco, Mexico
Research SiteZapopan, Jalisco, Mexico
Research SiteMonterrey, N.l., Mexico
Research SiteMexico City, Mexico
Research SiteBydgoszcz, Poland
Research SiteGdansk, Poland
Research SiteLublin, Poland

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy — TrialFind